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 Abstract 
 Background: The FAST (food allergy-specific immunothera-
py) project aims at developing safe and effective subcutane-
ous immunotherapy for fish allergy, using recombinant hy-
poallergenic carp parvalbumin, Cyp c 1.  Objectives:  Preclin-
ical characterization and good manufacturing practice 
(GMP) production of mutant Cyp (mCyp) c 1.  Methods:  Esch-
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erichia coli -produced mCyp c 1 was purified using standard 
chromatographic techniques. Physicochemical properties 
were investigated by gel electrophoresis, size exclusion 
chromatography, circular dichroism spectroscopy, reverse-
phase high-performance liquid chromatography and mass 
spectrometry. Allergenicity was assessed by ImmunoCAP in-
hibition and basophil histamine release assay, immunoge-
nicity by immunization of laboratory animals and stimula-
tion of patients’ peripheral blood mononuclear cells (PBMCs). 
Reference molecules were purified wild-type Cyp c 1 (natural 
and/or recombinant). GMP-compliant alum-adsorbed mCyp 
c 1 was tested for acute toxicity in mice and rabbits and for 
repeated-dose toxicity in mice. Accelerated and real-time 
protocols were used to evaluate stability of mCyp c 1 as drug 
substance and drug product.  Results: Purified mCyp c 1 be-
haves as a folded and stable molecule. Using sera of 26 dou-
ble-blind placebo-controlled food-challenge-proven fish-al-
lergic patients, reduction in allergenic activity ranged from 
10- to 5,000-fold (1,000-fold on average), but with retained 
immunogenicity (immunization in mice/rabbits) and poten-
cy to stimulate human PBMCs. Toxicity studies revealed no 
toxic effects and real-time stability studies on the Al(OH) 3 -
adsorbed drug product demonstrated at least 20 months of 
stability.  Conclusion: The GMP drug product developed for 
treatment of fish allergy has the characteristics targeted for 
in FAST: i.e. hypoallergenicity with retained immunogenici-
ty. These results have warranted first-in-man immunothera-
py studies to evaluate the safety of this innovative vaccine. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Fish frequently cause IgE-mediated food allergy  [1] . 
Like some other foods (peanuts and tree nuts, and in the 
early years of life milk and egg), fish allergy often pres-
ents with severe, sometimes life-threatening symptoms 
 [1, 2] . Currently, the only treatment for food allergy is 
avoidance and rescue medication. The need for effective 
and safe immunotherapy for food allergy is clear, and 
initiatives to develop in particular oral or sublingual 
treatments are currently underway [ 3 , and references 
therein]. Over 15 years ago, subcutaneous immunother-
apy (SCIT) was evaluated for the treatment of peanut 
allergy using aqueous peanut extract  [4, 5] , i.e. without 
adsorption to aluminum hydroxide (alum), for example, 
as is commonly done for SCIT in Europe. Although 
these studies demonstrated a promising level of efficacy, 
severe unacceptable side effects were frequently ob-
served. Since then, further attempts to develop SCIT for 
food allergy were considered too dangerous. With the 
advent of recombinant technology, new avenues have 
opened up  [6] , as it offers the opportunity to modify al-
lergenic molecules into safer hypoallergenic derivatives 
using site-directed mutagenesis. On top of that, adsorp-
tion to alum may add a second layer of safety and effec-
tiveness.
 In 2008, the EU-funded FAST (food allergy-specific 
immunotherapy) project was started: one part aiming at 
the development of a subcutaneous treatment for fish al-
lergy based on an alum-adsorbed hypoallergenic mutant 
of the major fish allergen parvalbumin  [7, 8] . Parvalbu-
min has been reported to play a very dominant role, with 
the majority of fish-allergic patients being sensitized 
mainly to this allergen in a broad spectrum of fish species 
 [2, 9, 10] . The first parvalbumin identified and character-
ized as an allergen was the major codfish allergen, Gad c 
1  [11, 12] . Parvalbumins are calcium-binding muscle 
proteins of 10–13 kDa, which are very resistant to heat, 
denaturation and proteolysis  [10, 11] and are ubiquitous 
in most common dietary fish  [2, 7, 8] . They are character-
ized by three (of which two are active) helix-loop-helix 
Ca 2+ -binding domains  [13–15] , and Ca 2+ depletion was 
shown to reduce IgE binding to parvalbumin  [16] . Carp 
parvalbumin (Cyp c 1) covers most cross-reactive IgE 
epitopes present in the family of homologous fish parval-
bumins  [16] . Swoboda et al. [17] produced a recombinant 
version of Cyp c 1, and, in agreement with the impact of 
Ca 2+ depletion, they provided evidence that mutations in 
the two active Ca 2+ binding sites also resulted in signifi-
cantly reduced IgE binding  [8] . Based on these promising 
pilot data, the FAST project selected this mutant Cyp 
(mCyp) c 1 as a starting point for the development of an 
alum-adsorbed hypoallergenic parvalbumin vaccine for 
SCIT of fish allergy. In the present study, we describe the 
preclinical development of mCyp c 1 into a good manu-
facturing practice (GMP)-produced drug substance and 
alum-adsorbed drug product suitable to go into a first-in-
man phase I/IIa clinical immunotherapy trial.
 Materials and Methods 
 Patients’ Sera and Peripheral Blood Mononuclear Cells 
 Sera (n = 26) and peripheral blood mononuclear cells (PBMCs; 
n = 30) from adult patients with fish allergy proven by double-
blind placebo-controlled food challenge (DBPCFC; n  = 24) or 
cod allergy proven by open food challenge (n = 3) or a convincing 
history of cod-induced anaphylaxis (n = 3) from the 6 clinical 
centers participating in FAST (Madrid, Rome, Lódz, Athens, 
Reykjavik and Odense) were used to evaluate hypoallergenicity 
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and T-cell reactivity of mCyp c 1. In addition, patients further 
had to have a positive skin prick test for fish ( ≥ 5 mm, BIAL-Ari-
stegui, Bilabao, Spain) and serum IgE against recombinant Cyp 
(rCyp) c 1 and recombinant Gad c 1 ( ≥ 0.70 kU A /l). The study 
protocol was approved by the local ethics committee of each clin-
ical center and all patients gave written informed consent to be 
enrolled in the study.
 Allergens 
 Natural parvalbumin nCyp c 1 was purified from carp muscle, 
as described before  [18] . Recombinant wild-type (WT) parvalbu-
min Cyp c 1.01 (EMBL accession No. AJ292211, rCyp c 1) and the 
mutagenesis, construction,  Escherichia coli  expression and final 
purification of the hypoallergenic mCyp c 1.01 (mCyp c 1) were 
performed as described by Swoboda et al.  [8] , only using the pET-
28b+ vector (Novagen, New Orleans, La., USA) instead. Details of 
the production and characterization of non-GMP rCyp c 1 and 
GMP mCyp c 1 are described in the online supplementary mate-
rial (for all online suppl. material, see www.karger.com/
doi/10.1159/000371657).
 Physicochemical Characterization 
 The drug substance mCyp c 1 was physicochemically charac-
terized in depth to assess identity, purity, integrity, homogeneity, 
molecular mass and aggregation state, using 1D and 2D gel elec-
trophoresis, size exclusion chromatography (SEC), circular di-
chroism spectroscopy, reverse-phase (RP) high-performance liq-
uid chromatography (HPLC) and mass spectrometry (MS). These 
methods are described in the online supplementary material.  For 
quantification of rCyp c 1 and mCyp c 1, absorbance at 280 nm and 
the bicinchoninic acid protein assay kit (Sigma, Gillingham, UK) 
were used.
 Accelerated Stability Studies of mCyp c 1 
 Samples were stored in aliquots at five different temperatures: 
–80, –30, 4, 25 and 40   °   C. The temperature of the stored samples 
was monitored on a weekly basis. Samples were analyzed at base-
line (t = 0), and 3 and 6 months, using SDS-PAGE in conjunction 
with Coomassie staining, SEC and RP-HPLC, using the sample 
stored at –80  °  C as reference. After thawing the 3-month samples, 
a small aliquot (10 μl) was refrozen at –80  °  C for subsequent MS at 
the 6-month time point, together with the 6-month samples. De-
tails can be found in the online supplementary material.
 Assessment of Hypoallergenicity: ImmunoCAP Inhibition and 
Basophil Histamine Release Test 
 ImmunoCAP analysis was performed according to the manu-
facturer’s instructions (Thermo Fisher Scientific, Uppsala,  Sweden) 
using rCyp c 1 ImmunoCAPs (f355). For titrated IgE inhibition 
studies (inhibitor added in 10-fold dilutions from up to100 μg to 
less than 1 ng), 75 μl serum was mixed with 75 μl inhibitor (nCyp 
c 1, rCyp c 1 or mCyp c 1) and incubated at room temperature for 
1 h prior to ImmunoCAP analysis. PBS was used for the uninhib-
ited control. Results were expressed as percent inhibition com-
pared to the uninhibited control. In addition, concentrations 
needed for 50% inhibition were calculated for each serum-inhibi-
tor combination.
 Histamine release from basophil leukocytes was performed as 
previously described  [19] . Details are described in the online sup-
plementary material.
 Immunogenicity Assessment: Laboratory Animals and Human 
PBMCs 
 Female New Zealand White rabbits were immunized on day 
0 with 50 μg rCyp c 1 or mCyp c 1 three times using TiterMax 
( TiterMax USA Inc., Norcross, Ga., USA) as adjuvant. A booster 
was given on day 35 (25 μg of antigen in 100 μl of PBS three 
times). Plasma was collected before immunization and on days 
60 and 74. Further details can be found in the online supplemen-
tary material.
 Female BALB/c mice (6 weeks of age; n = 6) were immunized 
subcutaneously with three different concentrations (5, 10 and 
20 μg) of aluminum hydroxide-adsorbed mCyp c 1 or rCyp c 1, 
and boosted twice on days 18 and 36. Serum was collected before 
immunization, on days 18 and 36 (boosting), and 2 weeks after the 
last boosting via puncture of the tail vein. Detection of allergen-
specific mouse immunoglobulins by ELISA was done as described 
by Linhart et al.  [20] .
 To assess T-cell reactivity to mCyp c 1, rCyp c 1 and nCyp c 1, 
PBMCs from fish-allergic patients were purified locally at each 
clinical center using Lymphoprep (Medinor, Oslo, Norway) from 
30 ml heparinized blood and stained with carboxyfluorescein suc-
cinimidyl ester according to Parish et al.  [21] . Details are described 
in the online supplementary material.
 Formulation of mCyp c 1 Drug Products and Real-Time 
Stability Testing 
 Formulation, adsorption, filling, labeling and packaging of the 
final product, as well as the real-time stability testing are described 
in detail in the online supplementary material.
 Toxicity Studies 
 Acute Toxicity. For acute toxicity studies, the OECD fixed-
dose procedure (OECD Guideline 420) was conducted in two 
stages, a sighting study and a main study, on rodents (mice) and 
nonrodents (rabbits), to confirm the observations made in ro-
dents. Details are described in the online supplementary material. 
In short, a dose of 10 or 0.3 mg/kg body weight (BW) of alum-
adsorbed mCyp c 1 (rodents and nonrodents, respectively) was 
given subcutaneously to a single animal. If there were no signs of 
toxicity after 24 h, the dose was administered subcutaneously to a 
group of 4 rodent and 2 nonrodent animals, which were then ob-
served for 14 days for possible clinical signs. After the observation 
period, gross necropsy was performed and macroscopic signs 
were recorded.
 Repeated Dose. To provide information on possible toxic ef-
fects of alum-adsorbed mCyp c 1 during longer exposure, to iden-
tify possibly affected target organs and to provide an estimate of 
a no-observed-adverse-effect level of exposure, a 6-month repeat-
ed-dose study was performed, which followed the design of the 
planned clinical study in duration and injection of a weekly 
(maintenance) dose. Four groups (vehicle only, and 30, 100 and 
300 μg mCyp c 1/kg BW) of 30 male and 30 female mice, respec-
tively, were injected subcutaneously with the test substance once 
a week, over a period of 6 months. Samples were collected at the 
end of the study for hematology, clinical chemistry and histopath-
ological analysis as well as specific immunoglobulin determina-
tions to mCyp c 1. Clinical signs, morbidity and mortality, BW 
and water and food consumption were monitored during the ex-
perimental period. Details are described in the online supplemen-
tary material.
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 Results 
 mCyp c 1 Is a Stable, Mixed Monomeric and Dimeric, 
Folded Protein 
 Physicochemical characterization of non-GMP mCyp 
c 1 and rCyp c 1 revealed that both are folded proteins 
dominated by α-helices ( fig. 1 a, b). On the other hand, 
on SDS-PAGE ( fig. 2 ) and SEC, mCyp c 1 ( fig. 3 a, b) mi-
grated at slightly lower apparent molecular mass, sug-
gesting that the shape of the molecule most likely under-
went some degree of change. Also, using RP-HPLC, 
mCyp c 1 and rCyp c 1 migrated at slightly different po-
sitions ( fig. 4 ). MS analyses before (online suppl. fig. S1) 
and after 2D separation and trypsin digestion of non-
GMP mCyp c 1 (online suppl. fig. S2 and table S1) re-
vealed that the preparation next to the full-length mole-
cule also contained a slightly shorter version of mCyp c 
1 truncated C-terminally by 5 amino acids, and some mi-
nor contaminations with  E. coli -derived molecules. In 
the final GMP batch, these  E. coli -derived contamina-
tions were significantly reduced ( fig. 1 ; online suppl. fig. 
S3). Both mCyp c 1 and rCyp c 1 were also detected as 
dimers on SDS-PAGE ( fig. 2 ), as was confirmed by the 
MS analysis after trypsin digestion (online suppl. S2 and 
table S1). The apparent propensity to dimerize was ob-
served more dominantly for the mCyp c 1 than for the 
rCyp c 1. In accelerated stability testing, both rCyp c 1 
and mCyp c 1 proved to be very stable after 6 months at 
up to 25  °  C ( fig. 2 , as well as  1 ,  3 ,  4 b, c). In conclusion, the 
drug substance is stable and has a secondary structure 
very similar to the WT molecule, but the tendency to di-
merize is higher.
 mCyp c 1 Shows Significantly Reduced Allergenic 
Activity 
 Titrated ImmunoCAP inhibition experiments were 
performed using sera from 26 DBPCFC-proven fish-al-
lergic patients. Both nCyp c 1 and rCyp c 1 have very 
similar inhibitory potency ( fig. 5 a), on average reaching 
50% inhibition at a concentration of 0.1–1.0 μg/ml 
( fig. 5 b). For mCyp c 1, 50% inhibition was not reached 
in most cases (24/26), reaching a plateau below 25% inhi-
bition at 75 μg/ml on average. This level of inhibition was 
reached on average around 75 ng/ml for the WT mole-
 Fig. 1. Circular dichroism spectra of rCyp c 1 ( a ,  c ) and mCyp c 1 ( b ,  d ) molecules at t = 0 ( a ,  b ) and after sta-
bility studies (t = 6 months;  c ,  d ).
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cules, implying a 1,000-fold reduction in IgE reactivity. 
There were two clear exceptions where 50% inhibition 
was reached, but the reduction in IgE reactivity was still 
10- and 100-fold, respectively.
 Basophil histamine release testing was performed for 
24/26 patients tested in ImmunoCAP inhibition. Sensi-
tization of basophils with sera of 11/24 patients with DB-
PCFC-proven fish allergy did not result in significant 
histamine release, even with the WT molecule. This can 
most likely be explained by insufficient sensitivity of the 
basophil histamine release test for low-level specific IgE 
[median 3.9 kU/l, interquartile range (IQR) 1.4–5.4 
kU/l, vs. a median of 13.2 kU/l, IQR 9–23.8 kU/l for the 
sera that did facilitate release]. Histamine release with 
sera of the other 13 patients confirmed that mCyp c 1 
has a 100- to 1,000-fold reduction in allergenic activity 
( fig. 6 ).
 Immunization with mCyp c 1 Induces rCyp c 
1-Cross-Reactive IgG Antibodies in Mice and Rabbits 
 rCyp c 1 and mCyp c 1 were compared for immunoge-
nicity in rabbits and mice, using IgG recognition of the WT 
molecule as primary outcome. In both rabbits and mice, 
mCyp c 1 induced an IgG response that was cross-reactive 
with rCyp c 1. In mice, rCyp c 1 induced a slightly weaker 
response than mCyp c 1. In rabbits, the limited number of 
animals did not warrant such comparison ( fig. 7 ).
 mCyp c 1 Induces Specific T-Cell Responses 
 PBMCs from 14 fish-allergic patients were isolated 
and stimulated with rCyp c 1, nCyp c 1 and mCyp c 1. All 
three molecules induced weak but significant prolifera-
tion (online suppl. fig. S4).
 Alum-Adsorbed mCyp c 1 Lacks Toxic Effects 
 A non-GMP batch of mCyp c 1 was adsorbed to alum 
at 1.1 mg/ml protein (based on absorbance at A 280 nm) 
to 2 mg/ml of alum. This batch was used for acute and 
repeated-dose toxicity testing. A single subcutaneous ad-
ministration of 0.3 and 10  mg/kg antigen (in rabbits and 
mice, respectively) did not result in clinical signs of toxic-
ity in any of the animals during the 14-day observation 
period. No signs of toxicity were observed at necropsy nor 
were test-item-related effects on BW or BW gain ob-
served. Based on this study, the no-observed adverse ef-
fect level of mCyp c 1 is above 10 mg/kg BW in mice and 
above 0.3 mg/kg BW in rabbits. Based on average BWs of 
mice ( ∼ 30 g) and rabbits (2.5–3 kg), these quantities are 
>10,000 times and >300 times higher, respectively, than 
the highest dose foreseen in the protocol for the first-in-
man clinical trial, i.e. 60 μg per injection, being close to 
0.9 μg/kg BW for an average BW of 70 kg.
 A 26-week four-armed repeated-dose toxicity study 
was performed in mice, using alum alone (placebo) and 
three dose levels of alum-adsorbed mCyp c 1. The alum 
concentration in the three active arms was kept constant. 
With respect to food consumption, BW, clinical signs, 
clinical chemistry and hematological determinations and 
histopathological evaluations, no differences between 
mCyp c 1-treated mice and mice that had received pla-
cebo were observed. Pharmacodynamics were evaluated 
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by assessment of mCyp c 1-specific IgG1, IgG2a and IgE 
antibodies and total IgE responses (online suppl. fig. S5). 
There was a statistically significant (p  < 0.05) increase 
compared to the controls in all dose groups for specific 
IgG1, IgG2a and total IgE, and the low dose for specific 
IgE. There were differences between male and female an-
imals that are detailed in the online supplementary mate-
rial; however, we believe these differences are inherent to 
the known differences in immune response between sex-
es rather than the molecule used for injection.
 GMP Batch 
 A GMP batch has been produced and tested using the 
same methods as the preclinical non-GMP batch used for 
toxicity testing. The yield (after purification) was 58.6 mg/l. 
The GMP drug substance had characteristics similar to 
those reported for the non-GMP batch (online suppl. mate-
rial). The GMP drug substance was subsequently adsorbed 
to aluminum hydroxide (2 mg/ml) at a concentration of 0.7 
mg/ml. The product was filled and samples were taken to do 
a quality assessment, including a test for sterility, and to per-
form a real-time stability study. The methods and results are 
described in detail in the online supplementary material 
text and table S2. Based on these analyses and the outcome 
of the toxicity studies, ethical and regulatory approval has 
been obtained, making the product a suitable first-in-hu-
man safety phase I/IIa clinical trial in fish-allergic patients.
 Discussion 
 In the present study, we describe the preclinical de-
velopment of a drug product for first-in-man subcuta-
neous treatment of fish allergy. Why fish allergy? Al-
though the prevalence is certainly lower than that of 
peanut or tree nut allergy, the risk of severe reactions is 
shared with these more common allergies. Financial 
support from the European Union 7th Framework Pro-
gram has made it possible to develop a treatment for a 
rare but potentially severe disease. A more pragmatic 
 Fig. 3. SEC spectra of rCyp c 1 ( a ,  c ) and mCyp c 1 ( b ,  d ) at t = 0 ( a ,  b ) and after stability studies (t = 6 months;  c ,  d ).
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 Fig. 4. RP-HPLC spectra of rCyp c 1 and mCyp c 1 at t = 0 ( a ) and after stability studies (t = 6 months;  b ,  c ). 
0.0001
0
25
50
75
100
125
0.001 0.01 0.1 1 10 100
Inhibitor concentration (μg/ml)
Inh
ibit
ion
 of
 Ig
E b
ind
ing
 fo
r rC
yp 
c 1
 (%
)
a b
nCyp c 1
rCyp c 1
mCyp c 1
0
1
2
3
4
5
50
100
500
1,000
IC 5
0 (μ
g/m
l)
nCy
p c
 1
rCy
p c
 1
mC
yp 
c 1
p < 0.0001
 Fig. 5. ImmunoCAP inhibition experiments with rCyp c 1 on the ImmunoCAP and the natural and recombinant WT or mutant allergen 
as inhibitors.  a  Inhibition at different inhibitor concentrations.  b Concentration of inhibitor needed for 50% inhibition (IC 50 ). 
a
55 60 65 70
–20
30
80
130
180
230
280
330
380
430
A 22
0 n
m (
mA
U)
Time (min)
rCyp c 1
mCyp c 1
b
30 5040 60 70
0
50
100
150
200
250
300
350
400
450
A 22
0 n
m (
mA
U)
Time (min)
rCyp c 1 –80ºC
–40ºC
4ºC
25ºC
40ºC
c
30 5040 60 70
0
50
100
150
200
250
300
350
400
450
A 22
0 n
m (
mA
U)
Time (min)
mCyp c 1 –80ºC
–40ºC
4ºC
25ºC
40ºC
D
ow
nl
oa
de
d 
by
: 
Ic
el
an
d 
Co
ns
or
tiu
m
 - 
Ic
el
an
d 
Te
le
co
m
 (S
im
inn
)   
    
   
14
9.
12
6.
76
.1
 - 
8/
18
/2
01
5 
3:
59
:4
2 
PM
 Zuidmeer-Jongejan   et al.  Int Arch Allergy Immunol 2015;166:41–51
DOI: 10.1159/000371657
48
0 18 36 54
0
0.5
0.1
1.5
2.0
2.5
IgG
1 r
esp
on
se 
to 
rCy
p c
 1 
(OD
405
 nm
)
Days after immunization
rCyp c 1
a
0 18 36 54
0
0.5
0.1
1.5
2.0
3.0
2.5
IgG
1 r
esp
on
se 
to 
rCy
p c
 1 
(OD
405
 nm
)
Days after immunization
mCyp c 1
b
Con
trol
0
0.2
0.4
0.6
0.8
1.0
1.2
Im
mu
no
CA
P r
esp
on
se 
(IU
/m
l)
c
Befo
re im
mun
izat
ion
rCyp
 c 1
mCy
p c 
1
 Fig. 7.  a ,  b Development of rCyp c 1-specific IgG1 antibody re-
sponses obtained in BALB/c mice (n = 6) after subcutaneous im-
munization (10 μg protein/mouse) with rCyp c 1 ( a ) and mCyp c 
1 ( b ). Antibody levels were measured by ELISA and results are 
displayed as mean optical density (OD) values.  c Development of 
rCyp c 1-specific IgG antibody responses obtained in rabbits (n = 
2) 60 days after subcutaneous immunization with rCyp c 1 and 
mCyp c 1. Before immunization (pooled from n = 20) and control 
values (anti-dog responses, n = 8) are shown. 
0.1
–40
–20
0
20
40
60
80
100
120
1 10 100 1,000 10,000 100,000
His
tam
ine
 re
lea
se 
(ng
/m
l)
Allergen concentration (ng/ml)
nCyp c 1
rCyp c 1
mCyp c 1
 Fig. 6. Mean histamine release obtained 
from stripped basophils sensitized with se-
rum from fish-allergic donors (n = 13) with 
the natural and recombinant WT and 
mCyp c 1 molecule. 
D
ow
nl
oa
de
d 
by
: 
Ic
el
an
d 
Co
ns
or
tiu
m
 - 
Ic
el
an
d 
Te
le
co
m
 (S
im
inn
)   
    
   
14
9.
12
6.
76
.1
 - 
8/
18
/2
01
5 
3:
59
:4
2 
PM
 Development Hypoallergenic 
Parvalbumin for SCIT 
 Int Arch Allergy Immunol 2015;166:41–51
DOI: 10.1159/000371657
49
reason is that fish allergy is dominated by a single major 
allergen, parvalbumin. This is a clear advantage when 
developing a treatment based on recombinant allergen 
technology. Of course a parvalbumin-based treatment 
will cover most but not all fish-allergic patients, but pre-
selecting on a sensitization to parvalbumin is easy with 
currently available reagents for component-resolved di-
agnosis  [2] .
 Why did we choose the subcutaneous route? To the 
best of our knowledge, all current initiatives to develop 
immunotherapies for food allergies (e.g. to egg, milk and 
peanut) focus on the oral, sublingual or epicutaneous 
route  [22–27] . SCIT has a long track record for efficient 
treatment of respiratory (pollen and house dust mite) and 
insect venom allergies  [28–30] , inducing long-lasting tol-
erance  [31, 32] . Although sublingual treatments of respi-
ratory allergies have gained a substantial market share, 
patient compliance is generally regarded as poor com-
pared to injections given by a specialist in a well-con-
trolled setting  [33] . Immunotherapy for food allergy is 
most relevant for those patients at risk of developing se-
vere potentially life-threatening reactions. In particular 
for that group, well-controlled administration, where 
compliance can be monitored reliably by experienced 
specialists, is of utmost importance. This is underscored 
by the first oral and sublingual immunotherapy trials for 
food allergy, where in the majority of patients protection 
(desensitization) is lost within weeks after termination of 
the treatment  [34–36] . With this in mind, poor compli-
ance to a daily oral or sublingual administration may put 
patients with severe food allergies at risk of severe reac-
tions when resuming the treatment or when accidentally 
exposed to the food.
 On the other hand, the safety profile of subcutaneous 
treatment for food allergy piloted for peanut in the early 
90s of the previous century has been very poor. Aqueous 
peanut extract caused severe side effects requiring epi-
nephrine and other rescue medication at high frequency 
 [4] . Therefore, any strategy towards SCIT for food aller-
gies should have a significantly improved safety profile. 
In the FAST project, we developed a hypoallergenic mu-
tant of the major fish allergen parvalbumin, mCyp c 1, 
and adsorbed this molecule to aluminum hydroxide to 
further decrease the risk of allergic side effects. Alumi-
num hydroxide is widely applied in SCIT for respiratory 
and venom allergies in Europe, but not in the USA. The 
safety issues observed with the use of aqueous peanut ex-
tract for SCIT warrant a discussion in the USA about the 
use of alum for increasing the safety of SCIT for the treat-
ment of food allergies.
 Based on earlier reports with (hypoallergenic) recom-
binant vaccines  [37–40] and the current and earlier pre-
clinical data obtained with mCyp c 1 [41] , it is to be ex-
pected that the current mCyp c 1-based vaccine will in-
duce allergen-specific blocking of IgG antibodies that can 
inhibit mast cell and basophil triggering and IgE-facilitat-
ed antigen presentation  [42] . By conserving T-cell epit-
opes, the vaccine is also suitable to induce anti-inflamma-
tory Cyp c 1-specific regulatory T cells that will inhibit 
Cyp c 1-induced allergic inflammation  [43] .
 Overall, one can hypothesize that immunotherapy with 
mCyp c 1 will dampen Th2/IgE-skewed allergic immune 
responses by induction of blocking IgG/IgG 4 antibodies 
and of T reg /Th1-type responses  [44, 45] . Two alternative 
strategies for increasing safety and efficacy of immuno-
therapy under development are aiming at reducing the 
risk of anaphylactic side effects by either just targeting the 
T-cell arm (T-cell epitope peptide immunotherapy)  [46] 
or the induction of blocking IgG antibodies (B-cell epit-
ope peptides conjugated to immunogenic carrier pro-
teins) [ 44 , and references therein]. In FAST, the strategy 
was to develop a drug substance that unites these two 
complimentary strategies into a single molecule: a hypoal-
lergen with largely retained T-cell reactivity and the po-
tency to induce blocking of IgG antibodies. In addition, 
the molecule needed to have physicochemical properties 
that guaranteed sufficient stability for a future pharma-
ceutical product and proven absence of toxic properties in 
laboratory animals. This paper reports the successful de-
velopment of mCyp c 1 as a stable soluble molecule that is 
hypoallergenic and has retained its T-cell reactivity and 
potency to induce IgG antibodies that cross-react with the 
native allergen. Although on average an impressive 1,000-
fold reduction in allergenic activity was reached, for some 
patients the reduction was significantly less, i.e. 10-fold 
and 100-fold, respectively. Therefore, a skin test reagent 
for mCyp c 1 was formulated that will be used to prescreen 
patients for their individual sensitivity to the hypoaller-
gen. Although a positive skin prick test cannot be directly 
translated into possible side effects upon subcutaneous 
administration of alum-adsorbed mCyp c 1, it is an extra 
precaution that may help identifying patients that are 
more likely to develop potentially more severe side effects.
 Toxicity studies necessary to get permission for first-
in-man administration did not reveal any toxic effects. 
Acute toxicity showed that a single application of mCyp 
c 1 in mice at a dose level corresponding to 800-fold the 
highest anticipated absolute human dose, by using BSA 
normalization of the animal dose according to FDA 
guidelines  [47, 48] (or >10,000 times the maximum dose 
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